Making better business decisions and optimizing process control
The real-time monitoring and prediction system, SIMCA-online, constantly monitors processes to provide a continuous snapshot of the users’ operations.
New version of SIMCA -advanced data analytics and visualization program - unlocks the hidden gems that hold the secret to better decision-making and greater business success.
Sartorius Stedim Biotech (SSB) has introduced a new version of its SIMCA and SIMCA-online data analytical solutions, which are offered by its subsidiary Sartorius Stedim Data Analytics, formerly known as Umetrics.
Every day, businesses generate a vast array of data derived from a variety of different sources. This data holds the key to better performance. The challenge is to interpret this information in a meaningful way. However, with so many parameters and such vast system complexity to consider, it is hard to find a solution that is both powerful and smart enough. SIMCA, an established advanced data analytics and visualization program as part of the company’s proven Umetrics Suite, makes it possible to combine and analyse data from all sources to isolate, understand and act on the hidden gems that hold the secret to better decision-making and greater business success.
SIMCA’s multivariate data analysis engine enables companies to swiftly detect and analyse deviations from normal operating conditions by modeling an idealized process. Once this model is transferred into SIMCA-online, it serves as a valuable reference for your current production. The newly enhanced software offers an intuitive graphical interface and the flexibility to handle complex data, such as reworking, splitting and merging, and more. SIMCA projects can be uploaded directly to an available SIMCA-online server for real-time visualization of the process from a data point of view.
The real-time monitoring and prediction system, SIMCA-online, constantly monitors processes to provide a continuous snapshot of the users’ operations. It not only helps to identify when set parameters change, but also enables remedial action to be taken before production is affected, ensuring that product quality remains consistent. With this level of control, it is possible to maximize resource efficiency, minimize operational costs and benefit from increased confidence in end-product quality.
Among the new features in SIMCA-online is the self-service analytics capability, which allows anyone to create fundamental process models, regardless of their background. The new notification system, along with the new web client, gives the user peace of mind about the quality of production anywhere and anytime as this system provides an overview of the production processes on devices such as tablets or mobile phones. SIMCA and SIMCA-online have been developed according to GAMP5 and have been extensively tested and validated. These programs are also used by the EMA and FDA for Real-Time Release testing.
See what others don’tAs leading experts for analysing data, Sartorius Stedim Data Analytics helps companies in any industry, which include the pharma, chemical and food sectors, find the growth opportunities they need using the comprehensive Umetrics Suite. These solutions enable them to harness the wealth of data within an organization, identifying vital elements to improve the results of research, product development and manufacturing processes. With improved process understanding and more consistent product quality, users will be able to reduce risk, speed up time-to-market and accelerate business growth.
A complete solution encompasses software, training, support and project management. Also, Sartorius Stedim Data Analytics provides the backup of an international network.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.